Alimera Sciences (NASDAQ:ALIM) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a report issued on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Alimera Sciences in a research report on Thursday, February 23rd. Alliance Global Partners cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $11.00 to $4.50 in a research report on Monday, November 21st.

Alimera Sciences Stock Up 8.9 %

Shares of Alimera Sciences stock opened at $2.20 on Friday. The stock has a market capitalization of $15.40 million, a P/E ratio of -0.83 and a beta of 1.42. The company has a 50-day simple moving average of $2.57 and a 200 day simple moving average of $4.22. Alimera Sciences has a 12-month low of $1.86 and a 12-month high of $7.92.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC bought a new position in Alimera Sciences during the 4th quarter worth approximately $32,000. Susquehanna International Group LLP bought a new position in Alimera Sciences during the 4th quarter worth approximately $92,000. Renaissance Technologies LLC boosted its stake in Alimera Sciences by 2.3% during the 2nd quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock worth $698,000 after acquiring an additional 2,900 shares during the last quarter. Finally, Caligan Partners LP bought a new position in Alimera Sciences during the 4th quarter worth approximately $1,297,000. Institutional investors own 24.58% of the company’s stock.

Alimera Sciences Company Profile

(Get Rating)

Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.